Diabetes Obesity and Metabolism · 2022 · 92 citations · 33 references
MedicineEndocrinologyNuclear MedicineGastroenterologyGastrointestinal PharmacotherapyHuman NutritionGastrointestinal ImagingMedical Nutrition TherapyPolycystic Ovary SyndromeWeight ManagementDelayed Gastric EmptyingGastric Emptying AnalysisGastric Emptying DisordersGastric Emptying TimeGastric SecretionPlacebo ComparatorsPlacebo-controlled Efficacy AssessmentPolycystic Ovary Syndrome Pharmacotherapy
Abstract Aim To evaluate the effect of once‐weekly subcutaneous semaglutide 1.0 mg on the late digestive period of gastric emptying (GE) after ingestion of a standardized solid test meal by using technetium scintigraphy, the reference method for this purpose. Methods We conducted a single‐blind, placebo‐controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3‐40.8] years, body mass index 37 [30.7‐39.8] kg/m 2 ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks. GE was assessed after ingestion of [ 99mT c] colloid in a pancake labelled with radiopharmaceutical by scintigraphy using sequential static imaging and dynamic acquisition at baseline and at Week 13. Estimation of GE was obtained by repeated imaging of remaining [ 99mT c] activity at fixed time intervals over the course of 4 hours after ingestion. Results From baseline to the study end, semaglutide increased the estimated retention of gastric contents by 3.5% at 1 hour, 25.5% at 2 hours, 38.0% at 3 hours and 30.0% at 4 hours after ingestion of the radioactively labelled solid meal. Four hours after ingestion, semaglutide retained 37% of solid meal in the stomach compared to no gastric retention in the placebo group ( P = 0.002). Time taken for half the radiolabelled meal to empty from the stomach was significantly longer in the semaglutide group than the placebo group (171 vs. 118 min; P < 0.001). Conclusion Semaglutide markedly delayed 4‐hour GE in women with PCOS and obesity.
33
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Anne Flint, Anne Raben, Arne Astrup et al. · Journal of Clinical Investigation · 1998 · 1.4K citations · Full text
John E. Blundell, Graham Finlayson, Mads Axelsen et al. · Diabetes Obesity and Metabolism · 2017 · 634 citations · Full text